Turkish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

ellipticine/kusma

Bağlantı panoya kaydedilir
NesneKlinik denemelerPatentler
4 Sonuçlar

[2 N methyl 9 hydroxy-ellipticine in treatment of metastatic breast cancers (author's transl)].

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
A phase II trial was conducted in 57 patients with advanced metastatic breast cancer given 2-N-methyl 9-hydroxy-ellipticine (NMHE) as 100 mg/m2 weekly. Evaluation of response, after at least 4 injections, was possible in 46 patients. Two complete regressions (of 3 and 12 months) and 7 regressions of
Ellipticine and some derivatives are highly cytotoxic substances which kill L1210 cells at concentrations ranging form 10(-8) to 10(-6)M. Some compounds in this series bind with high affinity to DNA (affinity constant between 10(7) M-1 and 10(5) M-1) by intercalation between base pairs. The

[Hydroxy 9-methyl 2-ellipticinium acetate (NSC 264-137). Toxicologic study and therapeutic effect in 100 cancers (author's transl)].

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
A new derivative of ellipticine, hydroxy-9-methyl-2-ellipticinium acetate, was found to be a useful anti-tumor drug in advanced cancers which could not be treated any longer successfully by any other procedure. In our series of 100 patients, the best results were obtained with bone metastases from

Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule.

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
Retelliptine dihydrochloride (SR 95325 B, NSC D-626717-W) is an ellipticine derivative having a very high level of antitumor activity in resistant murine solid tumor models. We studied in a Phase I trial escalating doses of retelliptine using a single 2-hour IV infusion schedule. Data from other
Facebook sayfamıza katılın

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı

  • 55 dilde çalışır
  • Bilim destekli bitkisel kürler
  • Görüntüye göre bitki tanıma
  • Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
  • Aramanızla ilgili bilimsel yayınları okuyun
  • Şifalı bitkileri etkilerine göre arayın
  • İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın

Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır

Google Play badgeApp Store badge